David Harris,James DiNunzio,William A Marinaro,Sutthilug Sotthivirat,Chad David Brown,Sundeep Sudish Dhareshwar,Jesse Lee Kuiper,Yung-Chi Lee,Craig Alfred McKelvey,Michael McNevin,Elise Topol Miller,L
申请号：
US15750056
公开号：
US20180228826A1
申请日:
2016.07.29
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor； a first solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof； and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof； and optionally one or more excipients； and a second solid dispersion formulation, which comprises an HCV NS3 inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof； and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof； and optionally one or more excipients. The present disclosure is also directed to oral dosage forms, such as tablets or capsules comprising the disclosed blended compositions comprising the disclosed solid dispersion formulations, and the methods for making these solid dispersion formulations and pharmaceutical compositions.
